Weekly updateCompaniesAI-cruiterRecruiting
Passage Bio

Passage Bio

  • Founded: 2019

  • Location: Philadelphia, PA

  • Employee range: 50 - 200

  • Clinical stage: Clin1/Clin2

  • Therapy area: GM1 Gangliosidosis

  • Drug types: GEN, NEU, PED, RAR

  • Lead product: PBGM01

  • Product link: https://www.passagebio.com/our-science/pipeline/default.aspx

  • Funding: $154M stock Jan 2021; $248M IPO Feb 2020; $110M B Sep 2019; $115M A Feb 2019

  • Investors: OrbiMed, Frazier Healthcare Partners, Versant Ventures, Lily Asia Ventures, New Leaf Venture Partners, Vivo Capital, Boxer Capital of Tavistock Group, Highline Capital Management, Logos Capital, Sphera Funds Management


passagebio.comhome/default.aspx

linkedin.com

job board


Short description:

Gene Therapy

Drug notes:

PBFT02 Clin1/Clin2 frontotemporal dementia; PBKR03 Clin1/Clin2 Krabbe disease; PBML04 Clin1/Clin2 metachromatic leukodystrophy; PBAL05 RD ALS; 2 undisclosed programs RD Huntington's disease, epilepsy

Long description:

Contact us to add description: recruit@workinbiotech.com

Jobs:


Main
Home

Weekly update

Companies

AI-cruiter

Recruiting
© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com